Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Telomir Pharmaceuticals (NASDAQ:TELO) announced groundbreaking preclinical results showing its molecule Telomir-1 effectively reversed key Type 2 diabetes parameters in zebrafish models. The study demonstrated significant reductions in fasting plasma glucose levels, improved glucose homeostasis, and reversed insulin resistance to near pre-diabetic levels, supported by improved HOMA-IR values. The research, conducted with Pentagrit, tested two forms of Telomir-1 at three doses, showing dose-dependent efficacy in normalizing blood glucose and reducing insulin levels. The molecule's mechanism focuses on normalizing iron metabolism to reduce oxidative stress and improve insulin sensitivity. The company is expanding research into progeria, Alzheimer's, osteoarthritis, and cancer models.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato risultati preclinici innovativi che dimostrano come la sua molecola Telomir-1 possa efficacemente invertire parametri chiave del diabete di tipo 2 in modelli di pesci zebra. Lo studio ha evidenziato significative riduzioni dei livelli di glucosio plasmatico a digiuno, un miglioramento della regolazione del glucosio e un'inversione della resistenza all'insulina a livelli prossimi a quelli pre-diabetici, supportata da valori migliorati di HOMA-IR. La ricerca, condotta in collaborazione con Pentagrit, ha testato due forme di Telomir-1 a tre dosi, mostrando un'efficacia dose-dipendente nella normalizzazione della glicemia e nella riduzione dei livelli di insulina. Il meccanismo della molecola si concentra sulla normalizzazione del metabolismo del ferro per ridurre lo stress ossidativo e migliorare la sensibilità all'insulina. L'azienda sta ampliando la ricerca su progeria, Alzheimer, osteoartrite e modelli di cancro.
Telomir Pharmaceuticals (NASDAQ:TELO) anunció resultados preclínicos innovadores que muestran cómo su molécula Telomir-1 puede revertir de manera efectiva los parámetros clave de la diabetes tipo 2 en modelos de peces cebra. El estudio demostró reducciones significativas en los niveles de glucosa plasmática en ayunas, mejoró la homeostasis de la glucosa y revirtió la resistencia a la insulina a niveles cercanos a los prediabéticos, respaldado por valores mejorados de HOMA-IR. La investigación, realizada junto a Pentagrit, probó dos formas de Telomir-1 en tres dosis, mostrando una eficacia dependiente de la dosis en la normalización de la glucosa en sangre y en la reducción de los niveles de insulina. El mecanismo de la molécula se centra en normalizar el metabolismo del hierro para reducir el estrés oxidativo y mejorar la sensibilidad a la insulina. La compañía está ampliando la investigación en progeria, Alzheimer, osteoartritis y modelos de cáncer.
Telomir Pharmaceuticals (NASDAQ:TELO)는 자사 분자 Telomir-1이 제브라피쉬 모델에서 제2형 당뇨병의 주요 매개변수를 효과적으로 역전시켰다는 획기적인 전임상 결과를 발표했습니다. 이 연구는 공복 혈장 포도당 수치의 상당한 감소, 포도당 항상성의 개선, 그리고 인슐린 저항성이 거의 당뇨 전 단계로 역전된 것을 보여줍니다. 이는 개선된 HOMA-IR 값에 의해 뒷받침됩니다. Pentagrit와 함께 수행된 이 연구에서는 세 가지 용량으로 두 가지 형태의 Telomir-1을 테스트했으며, 혈당 정상화와 인슐린 수치 감소에서 용량 의존적인 효과를 나타냈습니다. 이 분자의 작용 메커니즘은 철 대사를 정상화하여 산화 스트레스를 줄이고 인슐린 민감성을 향상시키는 데 중점을 두고 있습니다. 이 회사는 프로제리아, 알츠하이머, 골관절염 및 암 모델에 대한 연구를 확대하고 있습니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a annoncé des résultats précliniques révolutionnaires montrant que sa molécule Telomir-1 inverse efficacement les paramètres clés du diabète de type 2 dans des modèles de poissons-zèbre. L'étude a démontré des réductions significatives des niveaux de glucose plasmatique à jeun, une amélioration de l'homéostasie du glucose et une inversion de la résistance à l'insuline à des niveaux proches de ceux pré-diabétiques, soutenue par des valeurs HOMA-IR améliorées. La recherche, réalisée avec Pentagrit, a testé deux formes de Telomir-1 à trois doses, montrant une efficacité dépendante de la dose dans la normalisation de la glycémie et la réduction des niveaux d'insuline. Le mécanisme de la molécule se concentre sur la normalisation du métabolisme du fer pour réduire le stress oxydatif et améliorer la sensibilité à l'insuline. L'entreprise élargit ses recherches sur la progeria, la maladie d'Alzheimer, l'arthrose et des modèles de cancer.
Telomir Pharmaceuticals (NASDAQ:TELO) hat bahnbrechende präklinische Ergebnisse veröffentlicht, die zeigen, dass ihr Molekül Telomir-1 wichtige Parameter des Typ-2-Diabetes bei Zebrafischmodellen effektiv umkehren kann. Die Studie zeigte eine signifikante Reduzierung der Blutzuckerwerte im nüchternen Plasma, eine Verbesserung der Glukosehomöostase und eine Umkehr der Insulinresistenz auf nahezu prädiabetische Werte, unterstützt durch verbesserte HOMA-IR-Werte. Die Forschung, die in Zusammenarbeit mit Pentagrit durchgeführt wurde, testete zwei Formen von Telomir-1 in drei Dosen und zeigte eine dosisabhängige Wirksamkeit bei der Normalisierung des Blutzuckers und der Reduzierung der Insulinwerte. Der Wirkmechanismus des Moleküls konzentriert sich darauf, den Eisenstoffwechsel zu normalisieren, um oxidativen Stress zu reduzieren und die Insulinempfindlichkeit zu verbessern. Das Unternehmen erweitert die Forschung zu Progerie, Alzheimer, Osteoarthritis und Krebsmodellen.
- Successful preclinical results showing reversal of key Type 2 diabetes parameters
- Demonstrated significant reduction in fasting plasma glucose levels
- Improved survival rates in treated subjects
- Novel mechanism of action addressing root causes versus symptom management
- Potential market opportunity in treating 800+ million adults globally affected by Type 2 diabetes
- Results to preclinical zebrafish models, requiring further validation in mammals
- Early-stage research with no human trial data yet
- Multiple additional studies needed before potential commercialization
Insights
The preclinical study results for Telomir-1 represent a potentially significant breakthrough in diabetes treatment. The key findings show reversal of hyperglycemia and insulin resistance to near pre-diabetic levels in zebrafish models, supported by improved HOMA-IR values and glucose clearance. The drug's novel mechanism targeting iron metabolism and oxidative stress differentiates it from current symptom-focused treatments.
However, several important caveats exist: The research is still in early preclinical stages using zebrafish models, which while useful, don't always translate to human outcomes. The
This early-stage data positions Telomir-1 as a potential first-in-class therapy targeting the underlying mechanisms of Type 2 diabetes rather than just symptoms. The market opportunity is substantial, with over 800 million adults affected globally. The drug's unique approach to normalizing iron metabolism could provide competitive advantages over existing treatments that have significant side effects.
The broad research pipeline spanning multiple age-related diseases (progeria, Alzheimer's, osteoarthritis, cancer) suggests significant platform potential but also raises concerns about resource allocation for a small-cap company (
Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root, achieving reversal to near pre-diabetic levels
MIAMI, FL / ACCESSWIRE / December 3, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels. These findings were supported by significantly improved Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values, a standard measure used to assess insulin sensitivity and resistance.
These effects were also accompanied by increased survival rates in treated subjects. These findings highlight Telomir-1's ability to potentially address the underlying mechanisms of Type 2 diabetes, setting it apart from currently approved diabetes therapies.
According to information published by the International Diabetes Foundation, Type 2 diabetes (both undiagnosed and diagnosed) impacts more than 800 million adults globally, with an annual healthcare cost exceeding
The new preclinical study results, conducted in a zebrafish diabetes model, suggest that Telomir-1 could offer a novel, transformative approach by targeting the underlying mechanisms of insulin resistance. By normalizing iron metabolism, Telomir-1 directly addresses oxidative stress and beta-cell damage. A key metric of success in this study was the significant reduction in HOMA-IR values. Lower HOMA-IR values indicate improved insulin sensitivity and better glucose regulation, which are critical factors in combating Type 2 diabetes. The reversal of insulin resistance to near pre-diabetes levels achieved by Telomir-1 underscores its groundbreaking potential as a transformative treatment.
Erez Aminov, Chairman and CEO of Telomir, commented "We have not only confirmed age reversal and improved longevity with Telomir-1 but have also observed its potential to reverse key parameters of type 2 diabetes. These findings, demonstrated in preclinical studies, support our belief that Telomir-1 could fundamentally transform the way we age as we expand our research into other age-related diseases."
This announcement aligns with the new Trump administration's healthcare strategy under the proposed leadership of Robert F. Kennedy Jr. as head of the Department of Health and Human Services (HHS). Telomir believes that the new administration's focus on addressing root causes of chronic diseases and supporting transformative therapies complements Telomir's vision of treating disease causes rather than just symptoms.
Study Overview and Results
In collaboration with the India-based research organization Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three different doses, in zebrafish models of Type 2 diabetes mellitus induced by a high-calorie diet. The study assessed key metabolic indicators, including fasting glucose levels, Oral Glucose Tolerance Test (OGTT) results, insulin concentrations, and HOMA-IR.
Key findings include:
Reversal of Hyperglycemia and Insulin Resistance: Telomir-1 demonstrated dose-dependent efficacy in normalizing blood glucose and reducing insulin levels, restoring glucose homeostasis.
Significantly Reduced HOMA-IR Values: Telomir-1 showed a substantial improvement in insulin sensitivity to near pre-diabetes values, underscoring its potential to mitigate insulin resistance.
Enhanced Glucose Clearance: Significant improvements in OGTT results highlighted Telomir-1's impact on glucose metabolism.
Increased Survival Rates: Treated models exhibited improved survival compared to controls, showcasing Telomir-1's comprehensive therapeutic potential.
A Novel Mechanism of Action
Telomir-1's novel mechanism of action focuses on addressing the systemic role of iron metabolism in a large variety of chronic diseases, including Type 2 diabetes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues. Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these underlying causes.
Expanding Research and Future Directions
Building on these remarkable results, Telomir is advancing additional research, including:
Progeria Studies: Evaluating Telomir-1's effects on human progeria cell lines and progeria nematode models to investigate its impact on accelerated aging and telomere function and stability.
Diabetic Mouse Models: Further validating Telomir-1's efficacy in mammalian model of Type 2 diabetes.
Alzheimer's Disease: Initiating studies to assess Telomir-1's potential in mitigating cognitive decline and neurodegeneration.
Osteoarthritis and Inflammatory Diseases: Evaluating Telomir-1's role in managing joint health and other age-related inflammatory conditions.
Cancer Models: Exploring Telomir-1's application in combating age-related oncological conditions.
Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, elaborated: "These findings confirm Telomir-1's potential to not only manage diabetes effectively but to fundamentally change how we view chronic disease treatment. By targeting the root causes of insulin resistance, Telomir-1 offers a potential paradigm shift in diabetes management. We plan on exploring Telomir-1 in other metal-overload related diseases as we seek to realize the molecule's full potential."
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the anticipated benefits of the preclinical testing results described herein, (ii) anticipated timelines and subject matter for additional preclinical and clinical testing of Telomir-1 and (iii) the potential therapeutic benefits of Telomir-1 generally.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What were the main findings of Telomir-1's diabetes study by TELO in December 2024?
How does Telomir-1 (TELO) treat Type 2 diabetes differently from current treatments?
What additional disease areas is TELO exploring with Telomir-1?
